Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma

Park, I.J.; Kim, H.C.; Yu, Chang Sik; Ryu, Min‐Hee; Chang, Hyo Won; Kim, J.H.; Ryu, Jin‐Sook; Yeo, Jun Sang

doi:10.1016/j.ejso.2006.05.019

Cited by 67 publications

(27 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…F-18-FDG-PET/CT can provide information on the biologic condition of metastatic LNs [13] , thus reflecting the malignant potential of LNs. Although F-18-FDG-PET/CT has been reported to be accurate in diagnosing primary CRC [14] , its sensitivity in detecting metastatic LNs from CRC has been addressed in few studies, with no consensus being achieved [4,7,[15][16][17] .…”

Section: Introductionmentioning

confidence: 99%

Impact of Fluorine-18 2-Fluoro-2-Deoxy-<smlcap>D</smlcap>-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer

Sasaki

Kawasaki²,

Sato³

et al. 2016

Dig Surg

View full text Add to dashboard Cite

Background/Aims: Although the diagnostic value of fluorine-18 2-fluoro-2-deoxy-D-glucose (F-18-FDG) positron emission tomography/computed tomography (F-18-FDG-PET/CT) in patients with colorectal cancer (CRC) has been reported, the association between the F-18-FDG uptake in metastatic lymph nodes (FDG_LN) and clinicopathological variables has not been fully investigated. We evaluated the diagnostic value of F-18-FDG-PET/CT in detecting LN metastasis from CRC, and the relationship between F-18-FDG-PET/CT-detecting LN metastasis and prognosis. Methods: We retrospectively analyzed the medical records of 370 patients who underwent preoperative F-18-FDG-PET/CT, followed by surgical resection for CRC between January 2007 and December 2010. We analyzed the sensitivity, specificity, and accuracy of F-18-FDG-PET/CT and CT in diagnosing metastatic LNs. Survival was analyzed in 115 patients with stage III CRC. Results: The sensitivity, specificity, and accuracy for detecting metastatic LNs using F-18-FDG-PET/CT were 56.8, 90.3, and 74.2%, and those for contrast-enhanced CT were 38.4, 95.5, and 65.0%, respectively. The accuracy of F-18-FDG-PET/CT was significantly associated with tumor depth and lymphatic involvement. In the survival analysis, cancer-specific survival and the disease-free survival were significantly shorter in patients with stage III CRC with FDG_LN than in those without FDG_LN. Conclusion: F-18-FDG-PET/CT had low sensitivity and high specificity for detecting metastatic LNs from CRC. FDG_LN independently predicted poor prognosis in patients with stage III CRC.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of Fluorine-18 2-Fluoro-2-Deoxy-<smlcap>D</smlcap>-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer

Sasaki

Kawasaki²,

Sato³

et al. 2016

Dig Surg

View full text Add to dashboard Cite

show abstract

“…Accordingly, it is now used in patients with pulmonary cancer (5-7), Hodgkin's lymphoma (8,9), head and neck cancer (10), and colorectal cancer (11)(12)(13) for diagnosis; monitoring of treatment; and as a prognostic tool. However, FDG-PET is currently not used for NE tumor imaging on a routine basis because these tumors are generally slow growing and, accordingly, have low glycolytic activity compared with many other malignancies that therefore may lead to a low sensitivity for FDG-PET.…”

mentioning

confidence: 99%

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors

Binderup

Knigge

Loft

et al. 2010

Clinical Cancer Research

425

287

View full text Add to dashboard Cite

Purpose:18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently not used on a routine basis for imaging of neuroendocrine (NE) tumors. The aim of this study was to investigate the prognostic value of FDG-PET in patients with NE tumors. Experimental Design: Ninety-eight prospectively enrolled patients with NE tumors underwent FDG-PET imaging. FDG uptake was quantified by maximal standardized uptake value (SUVmax). The prognostic value of FDG uptake, proliferation index, chromogranin A, and liver metastases were assessed.Results: During the 1-year follow-up, 14 patients died. The diagnostic sensitivity of FDG-PET was 58% (n = 57) and a positive FDG-PET result was associated with a significantly higher risk of death with a hazard ratio (HR) of 10.3 [95% confidence interval (CI), 1.3-78.9]. Thirteen of the 57 (23%) FDG-PET-positive patients died compared with 1 of 41 (2%) FDG-PET-negative patients. By univariate analysis, a SUVmax of >9 and a high Ki67 index were significant predictors of overall survival with a HR of 8.8 (95% CI, 2.7-28.7) and a HR of 2.6 (95% CI, 1.3-5.1), respectively. In a multivariate analysis including a SUVmax of >3, Ki67, and chromogranin A, SUVmax of >3 was the only predictor of progression-free survival (HR, 8.4; P < 0.001).Conclusions: This study shows a strong prognostic value of FDG-PET for NE tumors, which exceeds the prognostic value of traditional markers such as Ki67, chromogranin A, and liver metastases. FDG-PET may obtain an important role for NE tumors. Clin Cancer Res; 16(3); 978-85. ©2010 AACR.

show abstract

“…29 However, there are some groups of patients for whom FDG is not advised: pregnant or lactating women should avoid FDG unless the benefits outweigh the risks. Nursing mothers are advised that breastfeeding should be stopped for 12 hours, and close contact between mother and infant is discouraged within 12 hours of the injection.…”

Section: Magnetic Resonance Imagingmentioning

confidence: 99%

“…29,51 Previous models have attempted to incorporate patient management and quality of life impacts by distinguishing between resectable and unresectable metastases 51 or by distinguishing between hepatic and extra metastases. 29 Our evaluation distinguished between metastases at one site, and at multiple sites (extra metastases). Assigning a probability for each in the overall metastatic recurrence population.…”

Section: Metastatic Parametersmentioning

confidence: 99%

The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.

Brush

Boyd²,

Chappell³

et al. 2011

Health Technol Assess

115

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAThe value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of ...

show abstract

Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma

Cited by 67 publications

References 23 publications

Impact of Fluorine-18 2-Fluoro-2-Deoxy-<smlcap>D</smlcap>-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer

Impact of Fluorine-18 2-Fluoro-2-Deoxy-<smlcap>D</smlcap>-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors

The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.

Contact Info

Product

Resources

About